- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03898765
Dry Blood Spot Screening Test for Biliary Atresia(DBS-SCReBA)
Dry Blood Spot Screening Test for Biliary Atresia and Other Cholestasis Diseases
Study Overview
Status
Intervention / Treatment
Detailed Description
BA accounts for approximately 60% of the liver transplantations in infants younger than 1 year of age. The diagnosis of BA remains a clinical challenge because affected neonates have signs, symptoms, and serum liver biochemistry that are also seen in those with other causes of neonatal cholestasis.
The success of the Kasai procedure is varied, but a good outcome is correlated with an early diagnosis. Unfortunately, most BA are usually identified later and the average age at surgery is about 60 days. To address this problem, some research groups screen infants for the pale stools or measure bilirubin level in the serum. However, these screening programs have not yet to be implemented because of several reasons. Recently, the relative abundance of serum MMP-7 was suggested to have discriminatory features for infants with BA. Nevertheless, whether the level of MMP-7 elevates in newborn dry blood spot of BA is still undefined. In this study, we will explore a screening strategy based on DB, γ-GT or MMP-7 measurement in newborn screening blood spot, and identify whether DB , γ-GT or MMP-7 measurement in the newborn period could be sensitive and specific for BA.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Wei Cai, Pro
- Phone Number: 0821-25076441
- Email: caiw204@sjtu.edu.cn
Study Contact Backup
- Name: Jie Wen, Dr
- Phone Number: 0821-25076449
- Email: wenjie19860813@live.cn
Study Locations
-
-
-
Shanghai, China
- Shanghai Xinhua Hospital, affiliated to Shanghai Jiao Tong University, School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Neonates born in Shanghai
Exclusion Criteria:
- Subjects who do not agree with study protocol
- Subjects who join other clinical trials
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental:Dry blood spot screening
|
Dry blood spot measurement of biomarker for screening biliary atresia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Suspected BA
Time Frame: Three to Seven days after birth
|
MMP-7 with or without other one or two biomarkers (DB and γ-GT) > upper limit of normal value
|
Three to Seven days after birth
|
Collaborators and Investigators
Investigators
- Study Director: Wei Cai, Pro, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XH-BA-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biliary Atresia
-
Sarah Magdy AbdelmohsenCompleted
-
RenJi HospitalUnknownBiliary Atresia Intrahepatic Syndromic FormChina
-
Children's Hospital of Fudan UniversityCompletedBiliary Atresia Congenital Type 3China
-
Yonsei UniversityCompletedBiliary Atresia, Kasai Portoenterostomy Status
-
Institute of Liver and Biliary Sciences, IndiaUnknownPortal Hypertension, Biliary AtresiaIndia
-
Intercept PharmaceuticalsNot yet recruiting
-
Weibing TangRecruiting
-
Holterman, Ai-Xuan, M.D.T Rose Clinical, Inc.; Big Leap Research; Prometheus USARecruitingBiliary AtresiaUnited States, Vietnam, Pakistan
-
AlbireoRecruitingBiliary AtresiaNetherlands, United States, Spain, Italy, Taiwan, Korea, Republic of, France, Germany, United Kingdom, Canada, Belgium, China, Australia, Poland, Turkey, Malaysia, New Zealand, Hungary, Israel
-
Arbor Research Collaborative for HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
Clinical Trials on Dry blood spot screening
-
National Taiwan University HospitalEnrolling by invitationBiliary Atresia | Cholestasis in Newborn InfantTaiwan
-
University of UtahAlbert Einstein College of Medicine; University of California, San Francisco; National Human Genome Research Institute (NHGRI) and other collaboratorsCompletedNeonatal Screening
-
Universitaire Ziekenhuizen KU LeuvenGeneral Hospital GroeningeUnknown
-
University Hospital, RouenNot yet recruitingHepatitis B | Hepatitis C | AIDSFrance
-
Rennes University HospitalCompleted
-
University of La LagunaRecruiting
-
University of UlsterCompletedRheumatoid ArthritisUnited Kingdom
-
Hospices Civils de LyonUnknownEnd Stage Renal Disease | Fabry Disease | Renal DialysisFrance
-
Nonin Medical, IncCompletedCollect Blood Values With Induced Hypoxia, Induced Methemoglobinemia, and Induced Hypoxia and MethemoglobinemiaUnited States
-
University of OxfordMahidol Oxford Tropical Medicine Research UnitUnknown